AIRA Matrix Private Limited
801 , Dosti Pinnacle, Road No. 22, Wagle Industrial Estate, Thane (West), India
What we do:
AIRA Matrix is a technology company with a decade of experience in AI-based automation and predictive solutions for cancer diagnostics and preclinical drug development workflows. Headquartered in Mumbai, with sales teams in the US and UK, our team comprises 120 experts dedicated to advancing Artificial Intelligence applications in oncology, preclinical toxicology, and pathology. We offer preclinical solutions to the pharmaceutical, biotechnology, and CRO sectors, and address the clinical diagnostics and cancer care sectors with our healthcare diagnostics solutions. AI-based solutions aims to provide accurate diagnostic and prognostic information to aid precise risk stratification, personalize therapy, and potentially improve treatment outcomes. These AI-based tests enable the generation of crucial prognostic and predictive analytics with a faster turnaround, lower cost, and using lesser quantities of tissue compared to current standards of care.
In addition to AI-based diagnostic and prognostic applications, we also provide platforms and tools for quality control, including solutions for stain quality assessment, organ identification, and artifact quantification. These preanalytical solutions ensure rapid and timely quality checks of digital images to improve the turnaround time and accuracy of downstream analytical workflows. AI-based solutions aims to provide accurate diagnostic and prognostic information to aid precise risk stratification, personalize therapy, and potentially improve treatment outcomes. These AI-based tests enable the generation of crucial prognostic and predictive analytics with a faster turnaround, lower cost, and using lesser quantities of tissue compared to current standards of care. In addition to AI-based diagnostic and prognostic applications, we also provide platforms and tools for quality control, including solutions for stain quality assessment, organ identification, and artifact quantification. These preanalytical solutions ensure rapid and timely quality checks of digital images to improve the turnaround time and accuracy of downstream analytical workflows.
How we do this:
We provide AI-based solutions aims to provide accurate diagnostic and prognostic information to aid precise risk stratification, personalize therapy, and potentially improve treatment outcomes. These AI-based tests enable the generation of crucial prognostic and predictive analytics with a faster turnaround, lower cost, and using lesser quantities of tissue compared to current standards of care. In addition to AI-based diagnostic and prognostic applications, we also provide platforms and tools for quality control, including solutions for stain quality assessment, organ identification, and artifact quantification.
These preanalytical solutions ensure rapid and timely quality checks of digital images to improve the turnaround time and accuracy of downstream analytical workflows. Our platforms and solutions are available as ready-to-deploy products or as managed services. Furthermore, our team of domain and technical experts, along with a set of innovative annotation tools, enables us to provide services for the rapid development of custom AI solutions for various oncology and non-oncology applications
Modalities/ products we cover:
Modalities/products we cover – Artificial Intelligence-based products and services for Digital Pathology including –
1) Solutions for Preanalytical Quality Control
2) Diagnostic, Prognostic, and Predictive Solutions for Prostate, Lung, and Breast Cancer
3) Custom AI Development Services for Malignant and Non Malignant Lesions